Gilead's sofosbuvir gets EMA validation, now under assessment
The Fly on the Wall
2013 FDA Drug Approval Calendar
TheStreet.com
- Adcetris
- Amag Pharmaceuticals
- Amarin
- Antares
- Auxilium
- Aveo Pharmaceuticals
- Cubist Pharmaceuticals
- dabrafenib
- Delcath
- Depomed
- Dolutegravir
- drug approvals
- efinaconazole
- Entereg
- Feraheme
- Gilead
- GSK
- Melblez
- Merck
- Otrexup
- Seattle Genetics
- Sefelsa
- sofosbuvir
- suvorexant
- tivozanib
- Trametenib
- Valeant Pharmaceuticals
- Vascepa
- Xiaflex
- Zogenix
- Zohydro
Will Influenza A H7N9 Generate Opportunities For Pharma?
Seeking Alpha
ASCO '13 Preview: Gilead's Big Cancer Debut
TheStreet.com
5 Stocks Boosting The Drugs Industry Higher
TheStreet.com
Racing Toward the Next Hepatitis C Drug Approval
Motley Fool
Gilead's Hepatitis C Drug Sofosbuvir Offers Upside
Seeking Alpha
Leading Biotechs Act Well But Be Careful Not To Chase
Investors.com